Research ArticleCancer

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect

See allHide authors and affiliations

Science Translational Medicine  16 Sep 2020:
Vol. 12, Issue 561, eabb7661
DOI: 10.1126/scitranslmed.abb7661

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

A tale of two relapses

Allogeneic hematopoietic stem cell transplantation can offer a cure for patients with otherwise incurable hematologic cancers. It is a form of cancer immunotherapy, as the transplanted blood cells from a healthy donor help destroy remaining leukemic cells, a phenomenon called the graft-versus-leukemia effect. Unfortunately, patients can still relapse. To understand the mechanisms involved in such posttransplant relapses, Bachireddy et al. performed detailed genetic analysis of cancer cells from 10 patients with chronic lymphocytic leukemia who relapsed after transplant. The authors found two distinct patterns among these patients: early relapse, caused by preexisting treatment resistance, and late relapse, driven by immune-mediated evolutionary pressure.

View Full Text

Stay Connected to Science Translational Medicine